LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).

Photo by towfiqu999999 from unsplash

TPS1100Background: There is no clear standard of care to address the management of refractory CNS metastases in HER2+ MBC. The ongoing study (NCT03417544) is evaluating the efficacy of the combination… Click to show full abstract

TPS1100Background: There is no clear standard of care to address the management of refractory CNS metastases in HER2+ MBC. The ongoing study (NCT03417544) is evaluating the efficacy of the combination of Atezo with P and high-dose H for the treatment of CNS metastases in patients (pts) with HER2-positive MBC. Methods: This is a phase II, single arm, multi-center trial assessing the efficacy of Atezo with Pertuzumab plus high-dose H for the treatment of CNS metastases in HER2+ MBC. Participants will receive Atezo [1200mg every 3 weeks (q3w)], P (840-mg loading dose, then 420mg q3w), and high-dose H (6 mg/kg weekly for 24 weeks, and then q3w). Eligibility Criteria include pts with HER2+ MBC, at least one measurable CNS metastasis (≥10 mm), unequivocal evidence of new and/or progressive CNS metastases, and left ventricular ejection fraction (LVEF) ≥ 50%. Exclusion criteria include CNS complications for whom urgent neurosurgical intervention is needed; known leptomeningeal/brainstem metastases; and treatment ...

Keywords: metastases patients; cns metastases; high dose; treatment; mbc

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.